<DOC>
	<DOCNO>NCT02986685</DOCNO>
	<brief_summary>The research aim investigate whether trimebutine maleate combine rabeprazole improve clinical efficacy patient With refractory Los Angeles grade A B reflux esophagitis . A total 500 patient Grade A B reflux esophagitis refractory rabeprazole randomly divide two groups.One continue receive rabeprazole treatment , group receive extra oral trimebutine maleate 200 mg three time daily 4 week . The end study every patient improvement main symptom . The primary secondary analysis main symptom score , endoscopy result , Gastroesophageal reflux disease questionnaire（GerdQ ) score , Hospital Anxiety Depression Scale ( HADS ) score , Athens insomnia scale World Health Organization Quality Life-Bref ( WHOQOL-BREF ) scale score baseline final assessment .</brief_summary>
	<brief_title>Trimebutine Maleate Combined With Rabeprazole Patients With Grade A B Reflux Esophagitis Whose Symptoms Refractory Rabeprazole</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Esophagitis , Peptic</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Trimebutine</mesh_term>
	<criteria>1 . Patients typical symptom heartburn sensation , acid regurgitation , least 6 months.The symptom moderate severe least three day week 7 day prior enrollment , complicate Atypical extraesophageal symptom . 2 . Diagnosed upper gastrointestinal endoscopy within one month enrollment grade A B reflux esophagitis accord Los Angeles classification 1 . History endoscopic antireflux surgery , Fundoplication major gastrointestinal surgery . 2 . History chest abdominal radiotherapy . 3 . History grade C D reflux esophagitis , gastrointestinal disease Barrett 's esophagus , zollingerellison syndrome , gastric duodenal ulcer ( exclude ulcer scar ) , large ( &gt; 5cm ) hiatus hernia , malignant tumor , esophageal stricture , esophageal gastric Varices , hemorrhage perforation digestive tract , mechanical ileus , et al . 4 . The presence serious comorbidities ( liver , gallbladder , pancreas , spleen , kidney , heart , lung , blood system , endocrine , mental disease , autoimmunity metabolic disorder ) malignant tumor organ . 5 . Diagnosis endocrine , neurological autoimmunity disorder may seriously affect motility ( e.g . scleroderma gastroparesis ) , primary esophageal motility disorder ( achalasia , esophagospasm nutcracker oesophagus ) . 6 . Pregnancy lactation study followup period . 7 . Use antisecretory drug ( PPIs H2RA ) , eradication H pylorus , drug influence gastrointestinal motility , anticholinergic , antipsychotic within 4 week study . 8 . Contraindications trimebutine maleate rabeprazole . 9 . Use drug interaction study drug （e.g . cisapride , procainamide , clopidogrel ciclosporin ) , drug may affect result study ( e.g . antisecretory drug ( PPIs H2RA ) , prokinetics , mucosal protective drug anticholinergic ) , drug absorb depend acidity gastric fluid ( e.g.ketoconazole digoxin ) , CYP3A4 , CYP2C19 inhibitor study . 10 . Patients inability refuse consent , unable complete questionnaire , poor compliance treatment . 11. patient participate clinical trial 3 month study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Refractory reflux esophagitis</keyword>
	<keyword>Rabeprazole</keyword>
	<keyword>trimebutine maleate</keyword>
</DOC>